2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Clinical Procedures, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Immunology, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, Indolent Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3987 Real-world antimicrobial utilization following initiation of systemic anti-cancer therapy among patients with multiple myeloma in the United States

Batyrkhan Kuatov, Sakil Syeed2, Drew Roberts3, Deborah Kuk4, Aisara Chansakul5, Melike Inkaya Taskin6, Holger Bartz7
1 CSL Behring, Bern, Switzerland
2 CSL Behring, King of Prussia, Pennsylvania, United States
3 Datavant, Phoenix, Arizona, United States
4 Datavant, Phoenix, Arizona, United States
5 Datavant, Phoenix, Arizona, United States
6 CSL Behring, Istanbul, Turkey
7 CSL, Hattersheim, Germany

Background

Patients with multiple myeloma (MM) may initiate anti-cancer treatment with substantial supportive care needs that evolve throughout the treatment journey. As disease- and treatment-related immune dysfunction accumulates with lines of MM therapy and may contribute to secondary immunodeficiency, understanding real-world patterns of antimicrobial utilization may provide insight into the supportive care burden associated with MM management.

Methods

This retrospective descriptive study used Carelon's linked U.S. electronic health record and closed claims database, spanning 01 January 2020 to 30 November 2025. Patients were required to have ≥12 months of continuous medical and pharmacy enrollment before initiation of first observed anti-cancer treatment (index date) and no evidence of prior MM, NHL or CLL anti-cancer treatment. Claims-based outcomes included systemic antimicrobial utilization overall and by antimicrobial class (antibacterial, antiviral, antifungal), measured as treatment prevalence, claims per patient per month (PPPM), and days of antimicrobial exposure PPPM during follow-up. Antimicrobial utilization without a claims-based infection diagnosis in the preceding 28 days was also evaluated as a proxy for prophylactic antimicrobial therapy. Patients were followed for up to 364 days post-index, censored at disenrollment or end of available data. Analyses were conducted overall and stratified by any baseline systemic antimicrobial exposure during the 365-day period before treatment initiation.

Results

Of 1,838 eligible patients with MM initiating anti-cancer treatment, mean (standard deviation [SD]) age was 68.8 (10.6) years, 66.7% (n=1,226) were aged >65 years, and 56.7% (n=1,042) were male. Median follow-up was 365 days (Q1: 184, Q3: 365). Clinically relevant comorbidities included renal failure in 52.2% (n=959) of patients, diabetes in 32.2% (n=591), congestive heart failure in 19.2% (n=353), chronic obstructive pulmonary disease in 15.2% (n=279), and neutropenia in 14.2% (n=261). Immunoglobulin testing during baseline was observed in 59.8% (n=1,100) of patients. Index anti-cancer treatment included immunomodulatory drugs in 45.9% (n=843) of patients, proteasome inhibitors in 38.3% (n=704), and anti-CD38 monoclonal antibodies in 27.7% (n=510). Prior systemic antimicrobial exposure was common, occurring in 82.8% (n=1,522) of patients before anti-cancer treatment initiation. Baseline antibacterial exposure was observed in 65.7% (n=1,207), including 29.9% (n=550) with ≥1 antibacterial claim within 30 days and 52.8% (n=970) within 180 days before anti-cancer treatment initiation. During follow-up, 89.2% (n=1,640) received ≥1 systemic antimicrobial, including 88.0% (n=1,618) receiving oral antimicrobials, 79.3% (n=1,458) antivirals, 72.5% (n=1,332) antibacterials, 26.4% (n=486) non-oral antimicrobials, and 15.2% (n=279) antifungals. Mean (SD) antimicrobial utilization was 0.98 (0.97) claims PPPM, including 0.52 (0.44) antiviral claims PPPM and 0.42 (0.71) antibacterial claims PPPM. Antimicrobial utilization without a claims-based infection diagnosis in the preceding 28 days occurred at a mean (SD) rate of 0.52 (0.50) claims PPPM. Among antimicrobial-exposed patients, mean (SD) antimicrobial exposure was 19.0 (9.1) days PPPM and median exposure was 22.3 days PPPM (Q1: 12.6, Q3: 26.6). Patients with any baseline antimicrobial exposure (n=1,522) demonstrated consistently greater utilization during follow-up than patients without any baseline exposure (n=316), including higher use of any antimicrobial (92.0% vs 75.6%), antivirals (83.4%  vs 59.5%), antibacterials (75.7%  vs 57.0%), and antifungals (16.8% vs 7.6%). Median antimicrobial exposure was also longer among any baseline antimicrobial users (22.7 vs 17.3 days PPPM).

Conclusion

This real-world study demonstrated that systemic antimicrobial use was common before anti-cancer treatment initiation and remained common after anti-cancer therapy initiation among patients with MM. Antimicrobial exposure was sustained throughout follow-up, with exposed patients receiving therapy for a median of 22.3 days per month, suggesting near-continuous use in this population. Overall, these findings highlight a substantial infection-related supportive care burden among patients with MM initiating anti-cancer systemic therapy and support future research to better characterize patients with persistent antimicrobial requirements and their underlying infection susceptibility.

Batyrkhan Kuatov: CSL Behring - Current equity holder in publicly-traded company; CSL Behring - Current Employment